Home
Search
Study Topics
Glossary
|
|
|
|
|
Tracking Information | |
---|---|
First Received Date ICMJE | July 19, 2004 |
Last Updated Date | June 19, 2006 |
Start Date ICMJE | July 2004 |
Current Primary Outcome Measures ICMJE | |
Original Primary Outcome Measures ICMJE | |
Change History | Complete list of historical versions of study NCT00087997 on ClinicalTrials.gov Archive Site |
Current Secondary Outcome Measures ICMJE | |
Original Secondary Outcome Measures ICMJE | |
Descriptive Information | |
Brief Title ICMJE | A Study of STA-4783 in Combination With Weekly Paclitaxel for Treatment of Patients With Soft Tissue Sarcomas |
Official Title ICMJE | |
Brief Summary | The purpose of this study is to evaluate the safety and effectiveness of an experimental study drug (STA-4783) combined with an approved cancer medicine, paclitaxel, in the treatment of soft tissue sarcomas. Paclitaxel (Taxol®) has been approved and used in the United States since 1992. |
Detailed Description | STA-4783 is a taxane potentiator, enhancing the effect of antitumor response of paclitaxel. In an attempt to improve efficacy, paclitaxel is sometimes used in combination with other anticancer agents. When paclitaxel is combined with other anticancer agents, although response rate is usually increased, side effects are usually increased as well. There is an urgent need for agents that can enhance the antitumor effects of paclitaxel without further increasing undesirable side effects. |
Study Phase | Phase II |
Study Type ICMJE | Interventional |
Study Design ICMJE | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study |
Condition ICMJE | Soft Tissue Sarcoma |
Intervention ICMJE | Drug: STA-4783 |
Study Arms / Comparison Groups | |
Publications * | |
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline. |
|
Recruitment Information | |
Recruitment Status ICMJE | Completed |
Enrollment ICMJE | 80 |
Completion Date | October 2005 |
Primary Completion Date | |
Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria:
|
Gender | Both |
Ages | 18 Years and older |
Accepts Healthy Volunteers | No |
Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects |
Location Countries ICMJE | United States, Canada |
Expanded Access Status | |
Administrative Information | |
NCT ID ICMJE | NCT00087997 |
Responsible Party | |
Study ID Numbers ICMJE | 4783-04 |
Study Sponsor ICMJE | Synta Pharmaceuticals, Corp. |
Collaborators ICMJE | |
Investigators ICMJE | |
Information Provided By | Synta Pharmaceuticals, Corp. |
Verification Date | June 2006 |
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |